Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML)
NCT01394666 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150
Last updated 2016-07-11
Summary
The purpose of this study is to evaluate treatment patterns and associated outcomes for CP-CML patients who fail Imatinib 400 mg daily in a real-world setting.
Conditions
- Chronic Myeloid Leukemia
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-05-31
- Primary Completion
- 2012-12-31
- Completion
- 2012-12-31
More Related Trials
-
To Study the Impact of Stopping Therapy in Patients of CML With Molecular Remission
NCT03062436 ·Status: UNKNOWN ·Phase: NA
-
Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms
NCT01650467 ·Status: WITHDRAWN
-
An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years
NCT02174445 ·Status: TERMINATED ·Phase: PHASE3
-
Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)
NCT00171899 ·Status: COMPLETED ·Phase: PHASE4
-
Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib
NCT01564836 ·Status: UNKNOWN ·Phase: NA
-
Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
NCT00519090 ·Status: TERMINATED ·Phase: PHASE3
-
Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
NCT00129740 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
NCT03509896 ·Status: COMPLETED
-
A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
NCT05367765 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Pharmacogenomics Validation for Imatinib in Chronic Myeloid Leukemia
NCT01437202 ·Status: COMPLETED
-
Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)
NCT01221376 ·Status: UNKNOWN ·Phase: PHASE2
-
Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment
NCT00632255 ·Status: COMPLETED
-
Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years
NCT00219752 ·Status: COMPLETED ·Phase: PHASE2
-
Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase
NCT00481052 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation
NCT00219726 ·Status: COMPLETED ·Phase: PHASE2
-
Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
NCT00101088 ·Status: TERMINATED ·Phase: PHASE1
-
A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
NCT04694560 ·Status: WITHDRAWN
-
Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha
NCT01073436 ·Status: TERMINATED
-
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
NCT02130557 ·Status: COMPLETED ·Phase: PHASE3
-
Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
NCT01660906 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)
NCT01279473 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
NCT02272777 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response
NCT01043874 ·Status: COMPLETED ·Phase: PHASE4
-
Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia
NCT01294618 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations
NCT01131325 ·Status: TERMINATED ·Phase: PHASE4